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Does cytotoxicity of metallointercalators correlate with cellular uptake or DNA
affinity?
Abstract
The cytotoxicity of the metallointercalators,
[Pt(5,6-dimethyl-1,10-phenanthroline)(trans-1R,2Rdiaminocyclohexane)] 2+ ([56MERR]) and
[Pt(5,6-dimethyl-1,10-phenanthroline)(trans-1S,2Sdiaminocyclohexane)] 2+ ([56MESS]), towards A549
human lung cancer cells was examined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. The IC50 value obtained following exposure of A549 cells to [56MESS] for 4 h was
approximately three times smaller than that obtained when [56MERR] was administered under the same
conditions, indicating that the former complex displayed greater cytotoxicity. Both IC50 values were
greater than that obtained after exposure of A549 cells to cisplatin, demonstrating that the latter
compound was the most cytotoxic of the three examined. Microprobe synchrotron radiation X-ray
fluorescence (SR-XRF) analyses of metallointercalator-treated A549 cells showed that platinum became
localised in DNA-rich regions of the nucleus. In contrast, when the same cells were treated with cisplatin
the metal became distributed throughout the cell. Determination of the maximum concentration of
platinum present inside the cells using graphite furnace atomic absorption spectrophotometry (GFAAS) of
platinum-treated cells suggested that there was greater uptake of [56MERR] compared to [56MESS] by
the A549 cells, and that platinum uptake did not account for the greater toxicity of [56MESS], as assessed
by the MTT assay. Electrospray ionization mass spectrometric (ESI-MS) and circular dichroism (CD)
spectroscopic studies of solutions containing either [56MERR] or [56MESS], and a duplex hexadecamer
molecule, showed the two metallointercalators displayed very similar affinity towards the nucleic acid.
Overall these results indicate that the difference in cytotoxicity of the two platinum metallointercalators is
probably the result of variations in their interactions with other cellular components.
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The cytotoxicity of the metallointercalators, [Pt(5,6-dimethyl-1,10-phenanthroline)(trans-1R,2Rdiaminocyclohexane)]2+ ([56MERR]) and [Pt(5,6-dimethyl-1,10-phenanthroline)(trans-1S,2Sdiaminocyclohexane)]2+ ([56MESS]), towards A549 human lung cancer cells was examined using the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The IC50 value obtained
following exposure of A549 cells to [56MESS] for 4 h was approximately three times smaller than that
obtained when [56MERR] was administered under the same conditions, indicating that the former
complex displayed greater cytotoxicity. Both IC50 values were greater than that obtained after exposure
of A549 cells to cisplatin, demonstrating that the latter compound was the most cytotoxic of the
three examined. Microprobe synchrotron radiation X-ray ﬂuorescence (SR-XRF) analyses of
metallointercalator-treated A549 cells showed that platinum became localised in DNA-rich regions of
the nucleus. In contrast, when the same cells were treated with cisplatin the metal became distributed
throughout the cell. Determination of the maximum concentration of platinum present inside the cells
using graphite furnace atomic absorption spectrophotometry (GFAAS) of platinum-treated cells suggested
that there was greater uptake of [56MERR] compared to [56MESS] by the A549 cells, and that platinum
uptake did not account for the greater toxicity of [56MESS], as assessed by the MTT assay. Electrospray
ionization mass spectrometric (ESI-MS) and circular dichroism (CD) spectroscopic studies of solutions
containing either [56MERR] or [56MESS], and a duplex hexadecamer molecule, showed the two
metallointercalators displayed very similar afﬁnity towards the nucleic acid. Overall these results indicate
that the difference in cytotoxicity of the two platinum metallointercalators is probably the result of
variations in their interactions with other cellular components.

1.

Introduction

Cisplatin (cis-diamminedichloroplatinum(II)) is a clinically-used
metallodrug that is extremely effective for the treatment of testicular cancer, against which cure rates of 90% have been
reported.1,2 Unfortunately, the administration of cisplatin and its
analogues can also result in severe side effects, which include
neurotoxicity, ototoxicity and nephrotoxicity.3 In addition,
acquired resistance resulting from increased drug efﬂux from
cancer cells, mutations/alterations in drug targets, and deactivation of the drug, may also result.4,5 These issues have prompted
an enormous effort directed towards developing new platinum
compounds that display similar or greater levels of anticancer
a
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activity to cisplatin, but with reduced side effects. Despite the
preparation and testing of thousands of platinum compounds,4–6
only a handful have entered clinical use. Most of the latter compounds, such as carboplatin and oxaliplatin, display a similar
spectrum of anticancer activity to cisplatin, albeit in some cases
with lower toxicity to the patient. There is now general awareness that most so-called second generation platinum anticancer
agents interact with DNA in a similar fashion to cisplatin, and
that this is the origin of their similar proﬁles of biological
activity.5,7,8 As a consequence there is now growing interest in
developing new cytotoxic metallodrugs with different structures
to that of cisplatin, which enable their interaction with nucleic
acids by alternative DNA binding mechanisms (Fig. 1).7–9
Intercalation is a non-covalent method of binding to DNA
which results in unwinding of the double helix in order to facilitate π-stacking interactions between the π electron clouds of the
base pairs and the intercalating compound.10–12 Metallointercalators are metal complexes that possess planar aromatic ring
systems which can be inserted between DNA base-pairs, and
usually also possess an overall positive charge, which enables
additional stabilizing interactions with DNA.12–15 Owing to the
Dalton Trans., 2012, 41, 9417–9426 | 9417
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Fig. 1 Structures of the complexes examined in this study.

presence of the metal centre, metallointercalators often exhibit
geometries not found amongst organic compounds. This broadens the range of possibilities for formulating new drugs that can
bind in unique or targeted ways to speciﬁc DNA sequences and
structures.15
Investigations into metallointercalators date back to the pioneering studies of Lippard and co-workers in the late 1970s,
which centered on the binding of platinum complexes containing
terpyridine to calf thymus DNA.16–18 More recently, a number
of studies into the biological activity of platinum(II) metallointercalators containing phenanthroline, or one of several methylated
phenanthroline ligands, have been conducted by Aldrich-Wright
and co-workers.19–22 For the complexes, [Pt(en)(Mexphen)]2+
(x = 1, 2 or 4), it was found that the number and position of the
methyl groups on the phenanthroline ligand affect both DNA
afﬁnity and activity toward L1210 leukemia cells. Even greater
cytotoxicity was displayed by complexes containing the bulky
trans-1,2-diaminocyclohexane (dach) ancillary ligand, which is
also present in the clinically used anticancer agent oxaliplatin
([Pt(trans-R,R-1,2-diaminocyclohexane)(oxalate)]). The stereochemistry of the dach ligand was found to have a signiﬁcant
effect on cytotoxicity, with platinum metallointercalators containing the enantiomeric S,S-dach ligand exhibiting greater cytotoxicity than those containing R,R-dach.22 For example, in
cytotoxicity assays performed with the 5637 human bladder
cancer cell line and the murine leukemia L1210 cell line,
[Pt(S,S-dach)( phen)](ClO4)2 exhibited IC50 values of 0.091 and
0.13 μM, respectively, while for [Pt(R,R-dach)( phen)](ClO4)2
these values were 0.54 and 1.50 μM, respectively, following a
96 h treatment period.22 Both complexes displayed cytotoxicity
that was comparable to, or better than that exhibited by cisplatin,
for which the corresponding IC50 values were 0.31 and 0.50 μM,
respectively. Methylation of the achiral ligands in these
complexes also increased cytotoxicity, with [Pt(S,S-dach)(5-methyl-1,10-phenanthroline)]2+ and [Pt(S,S-dach)(5,6-dimethyl1,10-phenanthroline)]2+ ([56MESS]) displaying IC50 values of
0.033 μM and 0.0092 μM, respectively against the L1210 leukemia cell line.20
While there have been a multitude of studies that have shown
that metallointercalators can bind to isolated pieces of DNA in a
test tube, only a small number have demonstrated that they can
actually enter cells and reach the nucleus.23–25 Consequently, it
was decided to explore the cellular fate of metallointercalators,
and the role that DNA binding may play in their mechanism of
action, by comparing the results of experiments performed using
a suite of spectroscopic studies and biological assays, with the
metallointercalators [56MESS] and [56MERR] ([Pt(R,R-dach)(5,6-dimethyl-1,10-phenanthroline)]2+) shown in Fig. 1. The
overall cytotoxicity of the complexes was ﬁrst evaluated using
9418 | Dalton Trans., 2012, 41, 9417–9426

the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay,26 while graphite furnace atomic absorption
spectrophotometry (GFAAS) and microprobe synchrotron radiation X-ray ﬂuorescence (SRXRF) imaging were used to
compare the cellular uptake and localization, respectively, of the
platinum intercalators and cisplatin by A549 human lung cancer
cells. Microprobe SRXRF is a highly sensitive analytical technique that can detect elements such as platinum in cells at submicron resolution, without the need for radioactive or ﬂuorescent
labeling.27–29 It can be used to provide a qualitative measure of
the amount of platinum entering cells. The elemental mapping
abilities of the technique can provide information regarding platinum co-localization with phosphorus, zinc, calcium or other
elements naturally present in cells, thereby providing clues as to
whether the metallointercalator localizes primarily in the nucleus
or the cytoplasm of cells, or becomes distributed throughout.
The studies reported here were performed to compare the cellular
fate of each of the three platinum complexes (Fig. 1), and to see
if any correlations could be drawn with respect to differences in
their cytotoxicity.
The relative DNA binding afﬁnity of the two metallointercalators was also assessed, using electrospray ionization mass spectrometry (ESI-MS) and circular dichroism (CD) spectroscopy, to
see if any correlations existed between this property and cytotoxicity. We have shown that ESI-MS can provide information
about the number, relative amounts, and stoichiometry of noncovalent complexes formed in solutions containing double
stranded DNA (dsDNA) and metal complexes.30–33 ESI-MS was
used to examine the stability of the metallointercalators in the
cell medium employed in the cytotoxicity assays. Circular
dichroism (CD) spectroscopy has been widely employed in the
past to study non-covalent interactions of metal complexes with
calf thymus (CT) DNA, or other DNA molecules such as poly
(dA-dT)2 and poly(dG-dC)2.34–38 However, there have been relatively few studies that have used CD spectroscopy to investigate
interactions between metal complexes and short duplex DNA
molecules with discrete base sequences. It was, therefore, of
interest to see whether addition of the platinum metallointercalators discussed herein produce similar or different changes to the
CD spectrum of a duplex molecule, D2, to those observed previously on addition of octahedral metallointercalators containing
nickel(II) or ruthenium(II) to the same DNA.32,33

2.

Results and discussion

Prior to performing platinum uptake and cellular distribution
studies, the MTT assay was used to determine the IC50 values
for the metallointercalators and cisplatin with the A549 cancer
cell line. These concentrations were then used as a guide for
determining appropriate platinum concentrations for GFAAS and
microprobe SRXRF analyses in order to minimise cell death but
ensure detection of platinum within the cells. Table 1 shows the
results obtained from the MTT assays. The IC50 value for
cisplatin was 150 ± 40 μM, which indicates that this complex is
approximately 3.5 times more toxic than [56MESS] (IC50 =
520 ± 160 μM) and 10 times more toxic than [56MERR] (IC50 =
1540 ± 480 μM). The greater toxicity of cisplatin is probably
due to it being the only one of the three platinum complexes
This journal is © The Royal Society of Chemistry 2012
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Table 1 Summary of the IC50 values determined from the MTT assay
of A549 cells treated with platinum complexes for 4 ha
Complex

IC50 (μM)

Cisplatin
[56MESS]
[56MERR]

150 ± 40
520 ± 160
1540 ± 480
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a
Results represent the mean and standard deviation obtained from
triplicate assays

able to interact covalently with DNA. [56MESS] was found to
be three times more toxic than the isomeric [56MERR], indicating that the chirality of the dach ligand signiﬁcantly affects the
cytotoxicity of these complexes toward A549 cancer cells. While
the IC50 values were higher than those reported by Fisher et al.22
and Wheate et al.,20 this is expected due to shorter exposure
times (4 h vs. 96 h), the use of a different end point for measuring cell viability (MTT as opposed to crystal violet), and the use
of a different cell line. Importantly, however, the general trend in
the observed toxicity of the isomers mirrors that reported earlier
for a series of square planar(II) metallointercalators containing
different derivatives of phenanthroline, as well as either SS-dach
or RR-dach.39 For the latter complexes the IC50 values determined
using the L1210 murine leukemia cell line were between 3 and 10
times smaller when the ancillary ligand present was SS-dach.
There are several possible explanations for the difference in
cytotoxicity displayed by [56MERR] and [56MESS] towards the
A549 cancer cell line. These include differences in cellular
uptake, variations in the subsequent distribution of the complexes or their metabolites within organelles and throughout the
cytoplasm, and/or differences in how the complexes interact with
chiral biomolecules such as DNA and proteins.
GFAAS was used to investigate the ﬁrst of these possibilities
whereby platinum uptake in the A549 cells was measured
following treatment with cisplatin, [56MERR], or [56MESS].
Initially a preliminary uptake experiment was performed to
determine the ideal platinum dose (150 μM, 500 μM, or
750 μM) and exposure period(s) (2, 4, 24 and 48 h) that could
be used for comparison of all three complexes. It was found that
a dose of 500 μM Pt, facilitated platinum detection and allowed
discernment between the treatments. The 2 h exposure period
resulted in very little uptake, while the 48 h exposure period
resulted in a substantial loss (by >90%) in cell numbers and cell
integrity resulting in the predominance of cell debris. As such
the 4 and 24 h treatment periods have been reported.
Fig. 2 shows the results obtained from GFAAS analysis
of cells treated with DMEM (only), cisplatin, [56MERR], or
[56MESS] (all Pt complexes 500 μM Pt in DMEM). Fig. 1S†
shows the complimentary cell populations associated with each
treatment and the proportion of cells that stained positive for
trypan blue (i.e., loss of membrane integrity). It is apparent that
there was a drop in cell numbers associated with platinum treatment; approximately 5–10% for the 4 h exposure period and
approximately 60% for the 24 h exposure period. Of note is the
similarity between the cell populations resulting from treatment
with [56MERR] or [56MESS]. This suggests that the MTT assay
is either a more sensitive toxicity assay or that the observations
in Table 1 stem from more speciﬁc interactions.
This journal is © The Royal Society of Chemistry 2012

Fig. 2 GFAAS detection of platinum in A459 cells following exposure
to the speciﬁed platinum complexes (500 μM Pt) for 4 h or 24 h.
Columns represent the mean value and error bars represent the standard
deviations obtained from triplicate samples.

The platinum uptake, reported in Fig. 2, has been presented as
the platinum detected per cell, which includes the total cell
count. Importantly, those cells that stained positive for trypan
blue represent only a small proportion of the total cells for each
treatment, such that it is unlikely that the loss of membrane
integrity has signiﬁcantly contributed to the observed platinum
uptake.
Statistical analysis (ANOVA, Tukey-Kramer) of the platinum
associated with the 4 h treatment group showed signiﬁcant
uptake (P < 0.001) in each of the platinum-treated cell samples
compared with the control cells. It was also evident that the
cellular platinum was highest following the 4 h exposure to
cisplatin compared to [56MERR] and [56MESS]. Following
24 h exposure there was, once again, signiﬁcant platinum uptake
in the platinum-treated cells versus the control cells (cisplatin,
P < 0.001; [56MERR], P < 0.001; [56MESS], P < 0.01). Interestingly, platinum uptake was greatest in [56MERR]-treated cells
following 24 h exposure whereby the platinum concentration
per cell was 1.8 times higher than that of cisplatin (P < 0.001).
Importantly, the platinum uptake in [56MERR]-treated cells
was approximately 2 times higher than that associated with
[56MESS]-treated cells following 4 h treatment, and increased to
2.7 times higher than that of [56MESS] following the 24 h treatment period (P < 0.001). While this result contrasts that expected
based on the MTT assays, whereby [56MERR] was less toxic
than [56MESS], the result was conﬁrmed by two individual
GFAAS experiments (triplicate samples in each experiment) and
it was also consistent with the trend observed in preliminary
microprobe SRXRF analyses of A549 cells treated with equimolar (1 mM) [56MERR] or [56MESS] (ESI Fig. S2†).
Microprobe SRXRF imaging was performed on thin sections
obtained from A549 cells treated with each of the platinum complexes (equitoxic dose, IC50 values determined by the MTT
assay) to shed light on whether the differences in the cytotoxicity
Dalton Trans., 2012, 41, 9417–9426 | 9419
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of the platinum complexes might be attributed to their differing
targeting ability. Fig. 3a shows the elemental maps for sulfur,
phosphorus, zinc, and platinum generated from microprobe
SRXRF analysis of a typical untreated A549 cell. The range of
concentrations of each element found within the cell is included
above the elemental map. Inspection of the elemental map for
sulfur reveals the overall size and shape of the cell, since high
concentrations of this element are found throughout the cell
owing to its presence in the toluidine blue stain (that targets
DNA) and the proteins and enzymes found in both the nucleus
and cytoplasm. There are distinct regions within the cell where
both phosphorus and zinc are present in high concentrations.
These can be used to locate the nucleus which contains DNA as
well as zinc-rich proteins involved in DNA recognition and
binding. The highest concentrations of phosphorus are present in
speciﬁc regions of the nucleus where heterochromatin is present,

since this consists of densely packed DNA molecules.40 Not surprisingly, the microprobe SRXRF results indicate that only very
low amounts (background) of platinum were present within the
control cell.
Due to beamtime limitations, only the 4 h platinum exposure
periods were analysed, with the emphasis on establishing the
initial targeting ability of the platinum complexes before the
cells became saturated with platinum. Signiﬁcantly greater
amounts of platinum were present within cells treated with cisplatin. For example, inspection of the platinum elemental map
for a typical cisplatin-treated cell shown in Fig. 3b reveals a
maximum platinum concentration of 0.0665 μg cm−2, which is
four times greater than that in the untreated cell (0.016 μg cm−2).
Comparison of the elemental map for platinum, with those
for zinc and, in particular, phosphorus indicates that cisplatin
and/or its metabolites become distributed throughout the cell,

Fig. 3 Microprobe SRXRF elemental maps for A549 cells following treatment (4 h) with: (a) cell medium only; (b) cisplatin; (c) [56MERR] and (d)
[56MESS]. The elements are speciﬁed at the bottom of each column. Operating conditions include: Beam energy = 11.9 keV, Beam size = 0.2 ×
0.15 μm; Stepsize = 0.3 μm; Dwell time = 3 s/pt and Scan dimensions (H × V) = (a) 12 × 10 μm; (b) 11 × 11 μm; (c) 10 × 10 μm; (d) 10 × 10 μm.
9420 | Dalton Trans., 2012, 41, 9417–9426
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and not conﬁned to the nucleus. A widespread distribution
of platinum throughout the cell after treatment with cisplatin
was found in each of the four A549 cells examined (further
example shown in Fig. S3†), and is attributable to the
formation of covalent compounds with DNA in the nucleus, as
well as with various small peptides (e.g. glutathione) and proteins inside and outside the nucleus. This result is consistent
with previous results obtained by Hall et al.27 who used microprobe SRXRF analysis of A2780 ovarian cells treated with
20 μM cisplatin (24 h) to show platinum accumulated in both the
nucleus and the cytoplasm. In addition, transmission electron
microscopy of thin sections prepared from cisplatin-treated
A2780 ovarian cells revealed that platinum was in contact with
the plasma membrane, nuclear envelope, cytoplasm and nuclear
matrices.41
Cells treated with either [56MERR] or [56MESS] showed a
cellular distribution of platinum that was distinctly different to
that of cells treated with cisplatin, with typical examples of
elemental distribution maps shown in Fig. 3c and d for both
complexes. There is signiﬁcant co-localization of platinum with
both zinc and phosphorus, suggesting that the metallointercalator
accumulates in the nucleus within as little as a 4 h exposure
period. Close inspection of the elemental maps for these three
elements reveals a very uniform distribution of zinc throughout
the nucleus, whereas both platinum and phosphorus were found
in the same speciﬁc regions of this organelle (Fig. S3† shows
further results). This is consistent with the conclusion that the
metallointercalator is interacting primarily with DNA present in
the regions of the nucleus containing the heterochromatin. This
result is in contrast to that obtained by microprobe SRXRF
analysis of HepG2 hepatoma cells treated with arsenite, a nonintercalating metal complex that exhibits a low overall afﬁnity
towards DNA in other assays.42 In the latter case arsenite was
found to be localised in the euchromatin region of the nucleus
where the DNA is less densely packed and available to undergo
transcription.
The above results also suggest that the platinum metallointercalators probably remain intact after entering the cell, as loss of
either of the bidentate ligands would be expected to result in
additional, covalent binding interactions with proteins in the
cytoplasm. In order to provide further evidence that this assertion
was correct, ESI-MS was used to examine the stability of
[56MERR] and [56MESS] in DMEM over the time course of
the cellular uptake and cytotoxicity experiments. The results
obtained in the experiment performed with [56MESS] are presented in the ESI (Fig. S4†), and clearly demonstrate that this
complex remained intact over a period of 4 h. During this time
the abundance of ions from intact [56MESS] remained approximately the same, with all other ions present being attributable to
components of the cell medium, or non-covalent complexes
formed with the metallointercalator. Identical results were
obtained when the experiment was performed using [56MERR],
indicating that it too remained intact throughout the course of
cell toxicity studies. The stability of the metallointercalators is
due to the presence of two chelating ligands in the platinum
coordination sphere. In contrast, ESI-MS analysis of reaction
mixtures containing cisplatin and DMEM indicated that this
complex underwent reactions with components of the cell
medium.
This journal is © The Royal Society of Chemistry 2012

The microprobe SRXRF results described above demonstrate
that [56MERR] and [56MESS] accumulate speciﬁcally in the
nucleus of cells, and probably in greatest amounts in those
regions where heterochromatin is present. In contrast, cisplatin
becomes more widely distributed throughout cells, as a result of
being able to interact covalently with both proteins and DNA.
It is important to note that these results do not provide information about the mechanisms by which the platinum complexes
interact with DNA. Both [56MERR] and [56MESS] are likely to
interact with DNA using a variety of mechanisms, including
electrostatic attraction, dipole–dipole interactions, and intercalation. However, neither complex contains a ligand such as dppz
(dipyrido[3,2a:2′,3′-c]phenazine), which is renowned for its ability
to confer on metal complexes the ability to be inserted into the
DNA base stack. We have previously used microprobe SRXRF
to investigate the cellular distribution of [Ni( phen)2(dppz)]2+.43
In many respects the nickel distribution map resembled those
shown for platinum in Fig. 3c and d, in that it revealed a high
degree of co-localization between the metal on the one hand,
and both zinc and phosphorus. This suggests that [Ni( phen)2(dppz)]2+ also has a high propensity to interact with DNA, but
does not yield any speciﬁc information about the nature of those
interactions.
The absence of a correlation between the IC50 values derived
from the MTT assays (Table 1), the extent of metal uptake for
[56MERR] and [56MESS] (Fig. 2), and the demonstration that
both platinum metallointercalators accumulate in the cell in
regions where DNA is expected to be present (Fig. 3), led to the
consideration as to whether or not the difference in cytotoxicity
between these complexes is due to variations in their afﬁnity
towards the nucleic acid. This prompted investigations into the
binding of [56MERR] and [56MESS] towards a discrete duplex
DNA molecule (D2) using a combination of ESI-MS and CD
spectroscopy.
Fig. 4 shows the negative ion ESI mass spectra of free D2
(Fig. 4a) and solutions containing a 1 : 3 ratio of D2 with
[56MESS] (Fig. 4b) or [56MERR] (Fig. 4c). It is apparent from
comparison of Fig. 4a with Fig. 4b and c that the proportion of
free D2 (responsible for ions at m/z 1626.4 and 1951.9)
decreases signiﬁcantly following incubation with the platinum
complexes, as a result of the formation of non-covalent complexes. However, the ESI mass spectra of solutions containing
the different platinum isomers are qualitatively very similar to
each other. In both cases, the most abundant non-covalent complexes present in solution are those containing one or two platinum molecules bound to D2. Furthermore the relative
abundances of non-covalent complexes containing different
numbers of platinum molecules bound to D2 were very similar
between the two spectra. This indicates that the afﬁnities of
[56MESS] and [56MERR] towards D2 are very similar. An identical conclusion was reached after comparing the ESI mass
spectra of solutions containing a 6 : 1 ratio of either [56MESS]
or [56MERR], and D2.
Fig. 5 shows the induced CD spectra obtained between
200 and 360 nm, for solutions containing either [56MESS]
or [56MERR], and D2, with Pt : D2 ratios ranging from 0 : 1 to
10 : 1. The two principal components of the spectrum of a
solution containing only D2 (not shown) consisted of a large
positive CD band centred at 268 nm, and a smaller negative CD
Dalton Trans., 2012, 41, 9417–9426 | 9421
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Fig. 4 Negative ion ESI mass spectra of free D2 and solutions containing a 3 : 1 ratio of metal complex and D2: (a) free D2; (b) D2 +
56MESS; (c) D2 + 56MERR. ● = free D2; ▲ = D2 + 1 metal complex;
■ = D2 + 2 metal complexes; ♦ = D2 + 3 metal complexes;
= D2 +
4 metal complexes.

Pt : D2 ratios a positive CD band centred above 260 nm was no
longer evident, while the negative CD band at 245 nm increased
in ellipticity and split into two separate negative bands. At the
highest Pt : D2 ratio examined (10 : 1), both platinum complexes
gave a spectrum containing a positive CD signal with low ellipticity and a peak maximum at either 282 nm for [56MERR] or
284 nm for [56MESS]. In addition, both spectra contained
strong, negative CD bands centred at 232 and 252 nm.
The above spectral changes contrast dramatically with what has
been reported previously for solutions in which octahedral metal
complexes non-covalently interact with D2. For example, addition
of [M(phen)3]2+ (M = Ni, Ru), or complexes such as
[M(phen)2(L)]2+ (M = Ni, Ru; L = dpqC, dppz), which are
capable of interacting more strongly by intercalation to D2,
resulted in the positive CD band shifting to lower wavelengths
and increasing signiﬁcantly in ellipticity.32,33 Furthermore the
magnitude of the changes in ellipticity afforded an order of
relative binding afﬁnity that matched that obtained by several
other techniques.32 Addition of other complexes, such as
[Ru(Me4phen)2(dpqC)]2+ and [Ru(Me4phen)2(dpqC)]2+, resulted
in shifts to lower energy for the positive CD signal of D2 that
were accompanied by major enhancements in ellipticity.32 Therefore the changes in CD spectra caused by addition of the square
planar complexes examined here are distinct from those seen previously with octahedral complexes, and reﬂect the sensitivity of
this technique to changes in DNA structure (e.g. changes to base
stacking, degree of helical unwinding) brought about by small,
non-covalent binding molecules. Further evidence that addition of
the square planar platinum complexes resulted in different distortions to the structure of D2, than those elicited by octahedral complexes is provided by a comparison of the changes to the negative
CD band at 245 nm in the spectrum of D2. Whilst addition of
octahedral metal complexes generally had very little effect on the
position or magnitude of the ellipticity of this CD band,32,33
addition of either [56MESS] or [56MERR] resulted in the band
splitting into two separate components, both of which grew signiﬁcantly in ellipticity.
Comparison of the two spectra in Fig. 5 corresponding to the
solutions containing a Pt : D2 ratio of 10 : 1 shows that CD bands
are centred at almost identical wavelengths, and have almost identical ellipticities. This was true for each of the other Pt : D2 ratios
examined, and is consistent with the conclusion that [56MESS]
and [56MERR] have very similar DNA binding afﬁnities.

3.
3.1.

Fig. 5 Induced circular dichroism spectra of solutions containing
different ratios of either 56MESS or 56MERR, and D2: (a) solutions
containing 56MESS; (b) solutions containing 56MERR.

band at 245 nm. These values are consistent with those reported
previously for B-form DNA.44 Addition of the platinum complexes resulted in almost identical induced CD spectra. At low
9422 | Dalton Trans., 2012, 41, 9417–9426

Experimental
Materials

MilliQ™ (18.2 MΩ, Millipore) water was employed for the
preparation of all solutions. Cisplatin was obtained from SigmaAldrich, while [56MESS] and [56MERR] (as their diperchlorate
salts) were prepared using a procedure described previously.20
[Ni( phen)2(dppz)]2+ was synthesised by Jihan Talib, University
of Wollongong.33 Glutaraldehyde (25% (v/v) in H2O) was
obtained from Fluka while 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) was purchased from
Sigma-Aldrich (St Louis, USA). Ammonium acetate (98%,
NH4OAc), methanol (99.8%), ethanol (99.5%) and dimethylsulfoxide (DMSO, 99.9%) were purchased from Ajax Finechem
This journal is © The Royal Society of Chemistry 2012
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(Seven Hills, Australia). Dulbecco’s modiﬁed Eagle’s medium
(DMEM, 11885-084) was sourced from GIBCO Invitrogen,
while foetal bovine serum (FBS), penicillin and streptomycin
were purchased from Thermo Electron Corporation. Phosphate
buffered saline (PBS) tablets were purchased from Bacto Labs
(New South Wales, Australia) and trypsin was purchased from
Thermo Scientiﬁc (Utah, USA). Disposable pipettes and 96 well
plates were sourced from BD Falcon (Victoria, Australia), and
cell culture ﬂasks were purchased from Greiner Bio-One GmbH
(Frickenhausen, Germany). Spurrs resin and gold Finder grids
were purchased from ProSciTech (Queensland, Australia).

3.2.

Cell studies

A549 human lung cancer cells were supplied by Associate
Professor A. Ammit (University of Sydney) and were grown
from frozen semi-permanents following rapid thawing. Typically,
cells were grown in cell culture ﬂasks with 75 cm2 surface area,
and incubated in a 5% CO2 incubator at 37 °C (Revco Ultima,
USA) to maintain growth. The growth medium (GM) employed
for cell studies contained DMEM, FBS (10% (v/v)), penicillin
(100 IU mL−1) and streptomycin (100 μg mL−1). The cells were
subcultured twice a week to prevent overcrowding and cell death.

3.3.

MTT assays

The cytotoxicity of the platinum complexes towards the A549
cells was assessed using the MTT assay.26 Cells (1 × 105 in
100 μL GM) were seeded into a 96-well plate which was incubated in a 5% CO2 incubator at 37 °C for 24 h. The cells were
then treated with freshly prepared solutions of the platinum complexes prepared in DMEM (2 mL). The treatment protocol
involved the addition of platinum solution (100 μL of the appropriate concentration) to each well, and then returning the plate to
the 5% CO2 incubator at 37 °C for 4 h. After this period, the
treatment solution was removed by aspiration and each well was
washed twice with PBS solution (200 μL). GM was then added
to the wells, and the cells were re-incubated at 37 °C under a 5%
CO2 atmosphere for 24 h to allow them to recover. At the end of
this period the GM was removed by aspiration and MTT solution
(50 μL, 2 mg mL−1 in PBS) was added to each well. The plate
was then incubated in 5% CO2 at 37 °C for 4 h, after which the
MTT solution was carefully removed by aspiration to ensure that
none of the purple formazan crystals were also removed. DMSO
(200 μL) was added to each well to dissolve the crystals, and the
plate was agitated for 15 s, after which the absorbance of the
resulting solutions was measured at 570 nm using a Spectromax
250 microplate reader (Molecular Devices Corporation, USA)
with Softmax PRO 4.0 software. Absorption measurements at
630 nm were also recorded for background subtraction. The
measured absorbances were then converted to percentage cell
viabilities using eqn (1). All cell viabilities are reported as a mean
and standard deviation obtained from triplicate assays each of
which were generated from 6 replicate measurements performed
for each concentration of each metal complex and control.
Cell viability ð%Þ ¼

A570  A630 ðtreated cellsÞ
100
A570  A630 ðcontrol cellsÞ
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3.4.

GFAAS

A549 cells were seeded (1 × 106 cells per dish, 5 mL GM) into
60 mm cell culture dishes after which they were incubated for
48 h at 37 °C, 5% CO2. Following this period the GM was
removed and the cells were washed twice with PBS. Treatment
solutions of cisplatin, [56MERR] or [56MESS] (500 μM Pt in
5 mL DMEM) were applied to the cells for 4 h and 24 h at
37 °C. Control cells were also prepared in a similar manner but
were treated solely with DMEM for 4 and 24 h. At the completion of the treatment period, the treatment solution was collected and centrifuged to collect any ﬂoating cells. These cells
were combined with the adherent cells which were harvested
from the dishes using trypsin (2 mL, 0.25% in PBS). The resultant cell pellet was washed twice with PBS by centrifugation
(300 g, 5 min). The ﬁnal cell pellets were resuspended in 2 mL
of PBS, and the cells associated with each sample were scored
by removing 50 μL of cell suspension and adding to trypan blue
solution (50 μL, 0.5% w/v in PBS). After 5 min the proportion
of intact cells (those that appeared colourless) and those with
compromised membrane integrity (those that appeared blue) was
determined using a haemocytometer.
The cells were centrifuged to remove the PBS and washed
twice with sterile saline solution (0.9%, 2 mL). The supernatants
were removed and the cell pellets were freeze-dried for 2 h.
Nitric acid (40 μL, Tracepur, 69% v/v) was added to each Eppendorf tube and the dehydrated pellets were digested overnight.
The digested pellets were transferred to volumetric ﬂasks
(5.00 mL) and the volume was adjusted to produce a ﬁnal concentration of 0.6% v/v HNO3 (Tracepur, 2% v/v).
GFAAS was performed on the resultant solutions using a
PerkinElmer AAnalyst 600 atomic absorption spectrometer
equipped with the Winlab 32 AA Furnace program incorporating
Zeeman-effect background correction, an AS-800 autosampler
and an AA Accessory cooling system. A Pt hollow cathode lamp
(PerkinElmer) was employed at 265.9 nm with a slit width of
0.7 nm, to give an instrument energy reading of approximately
63 W. A certiﬁed Pt standard solution (1003 mg L−1 Pt, 2% HCl
v/v, PerkinElmer) was used to prepare the stock Pt standard
(100 μg L−1, 0.6% HNO3) for the calibration curve (correlation
coefﬁcients: 0.999301, 0.998997). A volume of 20 μL of analyte
(standard or sample) was atomised from the surface of the pyrolytic graphite-coated tube using the furnace operating conditions
presented in Table 2. The analyte reading was obtained during
stage 4 (atomisation) and Ar gas was used during the analysis.
Triplicate readings were measured for each of the triplicate cell
samples prepared for each treatment condition. Statistical analysis of the results was performed using the One-way Analysis of

Table 2 Graphite furnace operating conditions used for analysis of
Platinum in A549 cell digests
Stage

Temperature (°C)

Ramp (s)

Hold (s)

Gas ﬂow
(mL min−1)

Dry 1
Dry 2
Ash
Atomisation
Clean out

110
130
1300
2200
2450

1
15
10
0
1

30
30
20
5
3

250
250
250
0
250
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Variance (ANOVA), Tukey-Kramer Multiple Comparisons Test
using GraphPad InStat Version 3.10.
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3.5.

Microprobe SRXRF imaging

Microprobe SRXRF analysis of thin-sectioned cells was performed to determine the distribution of the metals and other
selected elements at subcellular resolution following treatment
with either cisplatin or one of the metallointercalators. Thin sections were prepared according to the procedure reported previously.29,45 Brieﬂy, A549 cells were seeded into 75 cm2 ﬂasks
containing GM (25 mL). Once cell adherence had occurred
(after 24 h), the GM was removed and the cells were treated with
solutions (20 mL) of the metal complexes in DMEM. The concentrations of metal complexes used corresponded to the IC50
values obtained from the MTT assays. The cells and treatment
solutions were then incubated for 4 h at 37 °C in a 5% CO2 incubator. At the end of this period, the treated cells were collected
(washings and harvested cells) and centrifuged at 300 g for
5 min (Labofuge 300, Heraeus) to produce a cell pellet. The
pellet was washed twice with PBS, and the cells ﬁxed in glutaraldehyde solution (2% in PBS) at room temperature for 2 h. The
cells were centrifuged to form a pellet and stored in PBS overnight at 4 °C. The cells were dehydrated by washing with incrementally increasing concentrations of ethanol, followed by ﬁve
washes with dry 100% EtOH. The cells were centrifuged
and resuspended between each washing to ensure sufﬁcient
dehydration. The cell pellet was then inﬁltrated with 50%
ethanol:50% Spurrs resin overnight at room temperature, followed by 100% Spurrs resin for 6–12 h (4 times) to ensure
removal of all traces of water. Finally, the cell suspension contained in the Spurrs resin was transferred to a Beem capsule, and
the cells were centrifuged to form a pellet. The Beem capsule
was cured at 60 °C for 12 h, and the block was thin-sectioned
(1 μm) using an UltraCut T microtome. The sections were
stained with toluidine blue, washed four times with MilliQ water
and mounted onto gold Finder grids.
Prior to analysis, the samples were inspected and
imaged using a Leica DMXRE Epi-ﬂuorescence/visual microscope (Leica, Germany) at 20× magniﬁcation. Speciﬁc cells
were chosen for analysis according to the following criteria:
(i) location away from the gold grid bars to reduce scatter
effects; and (ii) the presence of a distinct nucleus.
Microprobe SRXRF analyses of thin-sectioned cell samples
were performed under an atmosphere of helium at the 2-ID-D
beamline at the Advanced Photon Source (APS), Argonne
National Laboratory (Chicago, USA), using a monochromatic
11.9 keV X-ray beam. The beam was focused to ∼0.2 μm2 diameter using two stacked zone plates. The gold Finder grids (supporting the cell sections) were mounted on a high precision XYZ
motorised stage mount (PM20076).
X-rays were detected in ﬂuorescence mode using a Vortex EM
(Radiant Detector Technologies, LLC 165-VTX-EM) silicon
drift detector. Typically a low resolution map (2.5 μm stepsize,
40 × 40 μm2 and 1 s per point dwell time) was initially collected
to determine the exact coordinates and scan dimensions for cell
maps. High resolution images were then collected using 0.2 μm
steps and a 3 s per point dwell time. Elemental images were
9424 | Dalton Trans., 2012, 41, 9417–9426

prepared with the use of the MAPS version 1.6.0 software
package provided by Dr Stefan Vogt at APS.46 The full ﬂuorescence spectra were ﬁtted to modiﬁed Gaussians with the aid of
corresponding measurements from the thin ﬁlm standards,
NBS-1832 and NBS-1833, obtained from the National Bureau
of Standards (Gaithersburg, MD, USA). Selected elemental
maps obtained after treatment of A549 cells with different metal
complexes are presented in Fig. 3. Additional elemental maps
are available in the ESI.†
3.6. ESI-MS stability studies of platinum complexes in cell
media

The stability of the metallointercalators in DMEM was studied
using positive ion electrospray ionization mass spectrometry to
determine if they remain intact for the length of time employed
for cytotoxicity and cell uptake studies (4 h). Mass spectra of the
solutions were obtained immediately after preparation, as well as
after 2 and 4 h.
3.7.

DNA puriﬁcation and preparation

Oligonucleotides ( purchased in a deprotected ‘trityl off’ form)
were obtained from Geneworks (South Australia) and puriﬁed
as described previously.47 The two complementary single
strand sequences D2A and D2B were annealed to form the
double stranded DNA (dsDNA) molecule which will be referred
to as D2.
D2A = 5′-CCT CAT GGC CAT GAC C-3′
D2B = 5′-GGT CAT GGC CAT GAG G-3′
D2 = d(CCT CAT GGC CAT GAC C/GGT CAT GGC CAT
GAG G)
The concentration of stock solutions of the single strands D2A
and D2B were determined by measuring their A260 using UV
spectrophotometry. Aliquots of the stock solutions were then
mixed to prepare solutions with D2A : D2B ratios of 1 : 1,
1 : 1.5, 1 : 2, 1.5 : 1 and 2 : 1. These were annealed by ﬁrst using
a Speedivac freeze dryer to remove the solvent, adding 5 μL of
100 mM NH4OAc ( pH = 7.4), heating the resulting solutions at
63 °C for 15 min, and then allowing them to slowly cool to
room temperature overnight. ESI-MS was used to determine
which solution contained the highest proportion of dsDNA relative to its constituent single strands. The solution with a 1 : 1.5
ratio of D2A : D2B gave the greatest yield of dsDNA. This ratio
was, therefore, used subsequently to prepare all stock solutions
of D2 (1 mM D2 in 100 mM NH4OAc ( pH 7.4)).
3.8. ESI-MS studies of interactions between
metallointercalators and DNA

Stock solutions of the diperchlorate salts of [56MESS] and
[56MERR] were prepared by dissolving 0.2–1.0 mg of solid
compound in 1.00 mL of 100 mM NH4OAc ( pH = 7.4). Reaction mixtures were prepared by adding 1 μL of stock D2 (1 mM)
to appropriate volumes of stock solution of metal complex
chosen to give metal complex to dsDNA ratios of 1 : 1, 3 : 1,
6 : 1 and 10 : 1. Finally, 100 mM NH4OAc ( pH 7.4) was added
to produce a ﬁnal volume of 100 μL, 200 μL or 500 μL.
This journal is © The Royal Society of Chemistry 2012
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Mass spectral analyses of solutions containing the metallointercalators and DNA were performed using a Waters Ultima
ESI quadrupole time-of-ﬂight (ToF) mass spectrometer,
equipped with an electrospray ionization source set in negative
ion mode. The instrumental conditions used in these experiments
included: capillary voltage = 2.5 kV; cone voltage = 100 V;
source temperature = 25 °C; desolvation temperature = 80 °C;
desolvation gas ﬂow = 100 L h−1.
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4.

Conclusions

Each of the three platinum complexes examined was found
to be stable in cell media, and toxic toward the A549 cell line.
Of particular note was the observation that [56MESS] was about
three times more toxic than [56MERR] (as determined by the
MTT assay), in keeping with the results of previous cytotoxicity
studies employing platinum complexes that differ only by the
presence of the S,S-dach or R,R-dach ligand.39 The even greater
cytotoxicity of cisplatin is attributable to a different mechanism
of action, in which the platinum becomes covalently attached to
DNA. Microprobe SRXRF studies clearly showed a difference in
cellular distribution between cisplatin, and both [56MERR] and
[56MESS]. While the former complex was present throughout
the cell, both [56MERR] and [56MESS] accumulated speciﬁcally in those regions of the nucleus where the heterochromatin
is expected to be present. This is attributable to the very stable
structure of the two metallointercalators, which prevents these
complexes from undergoing aquation in a similar fashion to cisplatin, to form metabolites capable of binding covalently to peptides and proteins in the cytoplasm. In the absence of any initial
hydrolysis reactions, [56MERR] and [56MESS] are capable of
interacting with DNA by a variety of mechanisms that probably
include partial intercalation.
Experiments were conducted in an attempt to identify an
explanation for the greater cytotoxicity of [56MESS] compared
to [56MERR] as determined by the MTT assay. Both ESI-MS
and CD spectroscopy revealed only small differences in their
DNA binding afﬁnities, while microprobe SRXRF analysis
showed similar cellular localization of platinum in cells treated
with [56MERR] and [56MESS]. In contrast, the results of
GFAAS experiments indicated that there was signiﬁcantly
greater uptake of [56MERR] compared to [56MESS]. As this is
the opposite trend to the order of cellular toxicity for these two
complexes, other factors must also play a part in determining the
differences in cytotoxicity of [56MERR] and [56MESS].
For example, it will be important to probe the interactions of
these complexes with other biomolecules such as proteins, most
importantly the mitochondrial enzyme probed by the MTT assay
(mitochondrial reductase), in order to develop a fuller understanding of the origin of the difference in their cytotoxicities.
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